Insider Shareholders with Direct Ownership of Aquestive Therapeutics, Inc. (AQST)
This section provides a comprehensive overview of the insiders with direct ownership of Aquestive Therapeutics, Inc. (AQST). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Aquestive Therapeutics, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
|
Alexander Mark Schobel
Chief Innovation/Tech Officer |
228,371 | 156,687 | 984,476 $2.76 Million | 9 |
Mar 15, 2024
Reduced 4.83%
|
|
Daniel Barber
President and CEO |
781,343 | 37,938 | 845,364 $2.37 Million | 4 |
Mar 09, 2024
Reduced 4.3%
|
|
Keith J Kendall
CEO and President |
0 | 3,000 | 636,149 $1.78 Million | 2 |
Aug 26, 2021
Reduced 0.16%
|
|
Lori J Braender
SVP, General Counsel |
298,761 | 10,530 | 313,231 $877,046 | 4 |
Mar 09, 2024
Reduced 3.25%
|
|
Stephen Wargacki
Chief Science Officer |
257,500 | 14,937 | 267,963 $750,296 | 6 |
May 10, 2024
Added 3.6%
|
|
Carl N Kraus
Chief Medical Officer |
262,500 | 10,819 | 251,681 $704,706 | 3 |
Aug 09, 2024
Reduced 4.12%
|
|
A Ernest Toth Jr
SVP, Chief Financial Officer |
260,000 | 11,705 | 248,295 $695,226 | 3 |
Mar 09, 2024
Reduced 4.5%
|
|
Cassie Jung
Chief Operating Officer |
211,250 | 10,797 | 237,754 $665,711 | 5 |
Mar 10, 2024
Reduced 0.47%
|
|
Peter E. Boyd
See Remark |
193,543 | 8,370 | 237,628 $665,358 | 5 |
Mar 09, 2024
Reduced 3.4%
|
|
Ken W. Marshall
SVP, Chief Commercial Officer |
150,000 | 0 | 150,000 $420,000 | 1 |
Mar 09, 2023
Added 50.0%
|
| 61,901 | 37,500 | 99,486 $278,560 | 2 |
May 10, 2021
Reduced 27.38%
|
|
|
Sherry Korczynski
SVP Sales and Marketing |
25,000 | 0 | 25,000 $70,000 | 1 |
Jun 07, 2024
Added 50.0%
|
| 0 | 62,500 | 12,585 $35,238 | 1 |
Mar 09, 2021
Reduced 83.24%
|